Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 4/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.32 |
| ▸ | MAOA | P21397 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29132137 | 0.69 | ITGB3 (0.32) | ITGB3ITGA2B | |
| SCHEMBL27137149 | 0.69 | ITGB3 (0.50) | TPSAB1TPSD1TPSG1ITGB3ITGA2B | |
| SCHEMBL19022998 | 0.68 | CHRM4 (0.37) | ITGB3ITGA2B | |
| SCHEMBL22633470 | 0.68 | — | — | |
| SCHEMBL23035036 | 0.67 | TP53 (0.34) | — | |
| SCHEMBL14952431 | 0.67 | CYP4A11 (0.34) | ITGB3ITGA2B | |
| SCHEMBL29277070 | 0.67 | ITGB3 (0.41) | TPSAB1TPSD1TPSG1KDM1AITGB3 | |
| SCHEMBL4712402 | 0.67 | GABRA1 (0.39) | TPSAB1TPSD1TPSG1ITGB3ITGA2B | |
| SCHEMBL30889781 | 0.67 | KDM1A (0.32) | KDM1AITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL19210387 | 0.67 | NAMPT (0.34) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TPSAB1 1844/4885TPSD1 2555/4885TPSG1 2439/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TPSAB1 1844/4885TPSD1 2555/4885TPSG1 2439/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TPSAB1 1844/4885TPSD1 2555/4885TPSG1 2439/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TPSAB1 1844/4885TPSD1 2555/4885TPSG1 2439/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TPSAB1 1844/4885TPSD1 2555/4885TPSG1 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.